Skip to content
    Guidelines & Consensus

    Trends in Contralateral Prophylactic Mastectomy and Genetic Testing Following ASBrS Guidelines

    Reagan et alBreast Cancer Research and Treatment

    A retrospective cohort study across two academic healthcare systems evaluated whether clinical practice shifted following consensus statements published by the American Society of Breast Surgeons (ASBrS). In 2016, the ASBrS issued guidance discouraging contralateral prophylactic mastectomy (CPM) in average-risk women with unilateral breast cancer, followed by a 2019 recommendation to offer genetic testing to all breast cancer patients.
    The analysis included 6,203 women undergoing surgical resection for newly diagnosed unilateral stage 0 to III breast cancer between 2011 and 2020 at the University of Kentucky and the University of Minnesota. Patients were stratified into two cohorts: pre-guideline publication (2011–2015; n = 2,619) and post-guideline publication (2016–2020; n = 3,584).
    Although CPM rates showed a statistically significant decrease from 19% in the earlier cohort to 15% in the later cohort (p < 0.001), utilization remained relatively persistent despite societal discouragement. Concurrently, genetic testing uptake increased from 2% to 22% between the two intervals. Patient and tumor characteristics significantly associated with the decision to undergo CPM included younger age, white race, lobular tumor histology, larger tumor size, HER2-positive receptor status, and receipt of genetic testing. The findings highlight the need for further investigation into underlying drivers of surgical choice and targeted strategies to align clinical practice with societal guidelines.

    Key Takeaways

    • Contralateral prophylactic mastectomy rates decreased from 19% in 2011–2015 to 15% in 2016–2020 (p < 0.001) following consensus guidelines discouraging the procedure in average-risk unilateral breast cancer.
    • Genetic testing rates rose tenfold from 2% prior to 2016 to 22% in 2016 or later across the evaluated academic health systems.
    • Receipt of contralateral prophylactic mastectomy was independently associated with younger age, white race, lobular histology, increasing tumor size, HER2 positivity, and receipt of genetic testing.
    Read the original sourceBreast Cancer Research and Treatment